Securities regulators are looking into the joint bid by Valeant Pharmaceuticals and activist investor Bill Ackman for Allergan, Dow Jones reported.» Read More
As Bill Ackman said Herbalife needs to be shut down, the stock soared. Here's how much he may have lost in options alone.
Analyst Tim Ramey said assertions made by Bill Ackman during Tuesday's presentation are untrue, and Ackman is correcting the record.
Bill Ackman fired his latest shot at Herbalife Tuesday, but the company's stock mostly rose during the investor's presentation.
Bill Ackman, head of Pershing Square Capital Management, said his firm's presentation of a Herbalife investigation will "expose incredible fraud."
Herbalife is ramping up its rhetoric against arch-nemesis Bill Ackman.
John Paulson, founder of hedge fund firm Paulson & Co., said corporate M&A activity "will continue for the foreseeable future."
Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.
The S&P 500 may have rallied 6 percent during the first half of the year, but the average hedge fund appears to have trailed that substantially.
Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.
Valeant said it plans to launch an exchange offer to Allergan shareholders this week, soliciting proxies to call for a meeting to discuss its offer.
Allergan's board of directors announced on Tuesday that it has unanimously rejected a revised, unsolicited buyout offer from Valeant Pharmaceuticals.
Now that they've made-up, Bill Ackman tells CNBC he's trying to get Carl Icahn to sell Herbalife.
Valeant and ally Pershing Square prepared to take its $53.8 billion takeover bid for Allergan directly to shareholders.
A stellar 2013 boosted confidence for stockpickers, but hedge funds are suffering their worst start to a year since the financial crisis.
How was it possible that Bill Ackman's Pershing Square Capital had become Allergan's largest shareholder without anyone knowing? The NYT reports.
Activist investor William Ackman told Allergan's board that the CEO has a 'disabling' conflict of interest because a takeover means losing his job.
Jim Chanos of Kynikos Associates says he'll continue to bet against Caterpillar and China, as well as a few other names.
With a who's who of bankers and hedge fund titans in attendance, the Robin Hood Foundation's annual gala raised more than $60 million.
U.S. medical firm Allergan rejected the unsolicited takeover offer from Valeant Pharmaceuticals, saying it substantially undervalued the company.
Happy Monday and welcome to another wild and woolly week on Wall Street.